Elafibranor upregulates the EMT-inducer S100A4 via PPARβ/δ

• Main Authors: Zhang, Meijian, Barroso, Emma, Ruart, Maria, Peña, Lucía, Peyman, Mona, Aguilar-Recarte, David, Montori-Grau, Marta, Rada, Patricia, Cugat, Clara, Montironi, Carla, Zarei, Mohammad, Jurado-Aguilar, Javier, Camins, Antoni, Balsinde, Jesús, Valverde, Ángela M., Wahli, Walter, Palomer, Xavier, Vázquez-Carrera, Manuel
• Other Authors: Lee Kong Chian School of Medicine (LKCMedicine)
• Format: Article
• Language: English
• Published: 2024
• Subjects: Medicine, Health and Life Sciences; Metabolic dysfunction-associated steatotic liver disease; Epithelial-mesenchymal transition
• Online Access: https://hdl.handle.net/10356/174274
• Institution: Nanyang Technological University

Elafibranor is a dual peroxisome proliferator-activated receptor (PPAR)α and β/δ agonist that has reached a phase III clinical trial for the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD). Here, we examined the effects of elafibranor in mice fed a choline-deficient hig...